Sapu Nano and Oncotelic Therapeutics, Inc. ('Oncotelic” or the 'Company”) today announced that Vuong Trieu, Chief Executive Officer, will present the Company’s Deciparticle™ nanomedicine platform at ...

Former Rappta Therapeutics CEO and Ipsen Global Oncology Franchise Head joins as TREOS advances its off-the-shelf, ...

SynuSight Biotech (SynuSight), a clinical-stage biotech company focused on innovative pipeline development for ...

The collaboration aims to expand access to patient samples, enhance clinical validation, and accelerate the development of multiomic diagnostics in women's health.

Sequencing CAR T-cell therapy versus bispecific antibodies in myeloma increasingly hinges on MRD depth, transplant candidacy, ...

Collaboration aims to accelerate biomarker discovery, strengthen translational research capabilities, and support scalable ...

Prostate and bladder cancers are among the most common urological malignancies worldwide. Traditional diagnostic approaches, including tissue biopsy, ...

The partners will stop developing BIIB122 in an all-comer population, but Denali will keep evaluating it in those with LRRK2 pathogenic variants.

Vascular surgery is undergoing a fundamental shift towards personalized, data-driven care, with biomarkers playing an increasingly important role in ...

The Phase 2b LUMA study of BIIB122 in early-stage Parkinson’s disease did not meet its primary or secondary endpoints Based on data from the ...

In an all-comer PROC population, across multiple dose cohorts, manageable safety profile of the combination was observed with low frequency of high-grade adverse events; Activity ...

Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell ...